TABLE III.
Adverse events for sunitinib malate in patients with gastrointestinal stromal tumour who have developed resistance or who exhibit intolerance to imatinib mesylate
| Adverse effects | Sunitinib (n=202) | Placebo (n=102) |
|---|---|---|
| Grade 1/2 adverse effects (%) | ||
| Leucopenia | 52 | 5 |
| Neutropenia | 43 | 4 |
| Thrombocytopenia | 36 | 6 |
| Grade 3 hematologic adverse events (%) | ||
| Leucopenia | 4 | 0 |
| Neutropenia | 8 | 4 |
| Lymphopenia | 9 | 2 |
| Thrombocytopenia | 4 | 0 |
| Grade 3 non-hematologic adverse events (%) | ||
| Grade 1–3 fatigue | 34 | 22 |
| Hand–foot syndrome | 4 | 0 |
| Diarrhea | 3 | 0 |
| Hypertension | 3 | 0 |